{"entity":{"id":"checkmate-915","kind":"trial","name":"CheckMate 915","aka":[],"tldr":"CheckMate 915 asked whether adding a low dose of ipilimumab to nivolumab after melanoma surgery would prevent more recurrences; it did not, and added toxicity, so single-agent PD-1 blockade remains the adjuvant standard.","summary":"Nivolumab plus ipilimumab is the most active combination in advanced melanoma, and CheckMate 915 tested whether a lower-toxicity version (ipilimumab 1 mg/kg every six weeks) would improve on nivolumab alone after complete resection of stage IIIB to IV melanoma. It randomised 1844 patients, with recurrence-free survival in the whole population and in PD-L1-low tumours as the dual primary endpoints.\n\nThe combination did not improve recurrence-free survival in either population and caused more treatment-related adverse events. Adjuvant nivolumab or pembrolizumab alone remain the standards, and later trials have tested relatlimab (RELATIVITY-098) and neoadjuvant approaches (NADINA) instead.","status":"negative","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT03068455","url":"https://clinicaltrials.gov/study/NCT03068455"}],"tags":["subtype-trials"],"related":[],"cancers":["stage-iii-melanoma","melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jeffrey-weber"],"bottlenecks":[],"keyPapers":["paper-checkmate-915-j-immunother-cancer-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03068455","phase":"3","setting":"Resected stage IIIB to IV melanoma: adjuvant nivolumab plus low-dose ipilimumab against nivolumab alone","sponsor":"Bristol Myers Squibb","result":"Nivolumab plus low-dose ipilimumab did not improve recurrence-free survival over nivolumab alone after resection of stage III to IV melanoma.","started":"2017-04-11","startedType":"actual","yearReported":2022,"enrolled":1844,"enrolledBasis":"registry","outcomes":[{"endpoint":"Recurrence-free survival, all randomised participants (registry results)","primary":true,"unit":"months","arms":[{"name":"Nivolumab + ipilimumab","note":"Median not reached"},{"name":"Nivolumab","note":"Median not reached"}],"hr":0.9,"ci":[0.78,1.04],"source":"https://clinicaltrials.gov/study/NCT03068455?tab=results"},{"endpoint":"Recurrence-free survival, PD-L1 expression below 1% (registry results)","primary":true,"unit":"months","arms":[{"name":"Nivolumab + ipilimumab","value":33.15,"note":"95% CI 22.21 to not reached"},{"name":"Nivolumab","value":27.63,"note":"95% CI 19.81 to not reached"}],"hr":0.92,"ci":[0.75,1.14],"source":"https://clinicaltrials.gov/study/NCT03068455?tab=results"}]},"route":"/trials/checkmate-915/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"person":[{"id":"jeffrey-weber","kind":"person","name":"Jeffrey S. Weber","route":"/people/jeffrey-weber/"}],"paper":[{"id":"paper-checkmate-915-j-immunother-cancer-2025","kind":"paper","name":"Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915","route":"/key-papers/paper-checkmate-915-j-immunother-cancer-2025/"}],"idea":[{"id":"idea-tr1-extended-interval-checkpoint-dosing","kind":"idea","name":"Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable","route":"/ideas/idea-tr1-extended-interval-checkpoint-dosing/"},{"id":"idea-chronotherapy-immunotherapy","kind":"idea","name":"Give immunotherapy in the morning","route":"/ideas/idea-chronotherapy-immunotherapy/"},{"id":"idea-microbiome-io-fmt","kind":"idea","name":"Microbiome transplant as a routine immunotherapy adjunct","route":"/ideas/idea-microbiome-io-fmt/"},{"id":"idea-tr1-immunotherapy-stop-trials","kind":"idea","name":"Randomised trials of stopping immunotherapy after one year versus continuing","route":"/ideas/idea-tr1-immunotherapy-stop-trials/"},{"id":"idea-bio2-lymph-node-immune-priming","kind":"idea","name":"Treat the draining lymph node before removing it","route":"/ideas/idea-bio2-lymph-node-immune-priming/"}]}}